


What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Please see Important Safety Information throughout. Please see the full Prescribing Information for <u>VYVGART for IV infusion</u> and <u>VYVGART HYTRULO for subcutaneous injection</u>.



VYVGART is given in treatment cycles with a personalized break between each cycle



SELECT IMPORTANT SAFETY INFORMATION

Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART and VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Please see Important Safety Information throughout. Please see the full Prescribing Information for <u>VYVGART for IV infusion</u> and <u>VYVGART HYTRULO for subcutaneous injection</u>.

How personalized breaks may help you get the most out of your treatment plan



You'll work with your doctor to **personalize your breaks** between cycles based on your symptoms and side effects.



When your symptoms start to return, **talk to your doctor** to help them decide when you need another cycle.

For example: Your doctor may start you with a 4-week break after each of your first 3 treatment cycles. Your doctor will continue to adjust your time between additional cycles, based on your symptoms and side effects.

The safety of starting the next treatment cycle sooner than 4 weeks from the last treatment of the previous treatment cycle has not been established. If you miss a scheduled treatment, VYVGART may be given up to 3 days after the scheduled treatment day.

See what personalized breaks mean for real patients on VYVGART

Visit VYVGARTStories.com to find out more.

SELECT IMPORTANT SAFETY INFORMATION

VYVGART and VYVGART HYTRULO may cause serious side effects, including infection. VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.

Please see Important Safety Information throughout. Please see the full Prescribing Information for <u>VYVGART for IV infusion</u> and <u>VYVGART HYTRULO</u> <u>for subcutaneous injection</u>.

SYMPTOM TRACKING



Tracking your symptoms consistently is important

Starting your next treatment cycle is based on your doctor's evaluation of your symptoms and any side effects you may experience. Use the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale to help track your symptoms.



Consistently track your symptoms. If you track them weekly, try to do it at the same time each week.



Use the MG-ADL scale on page 5 to track your symptoms.



Share your MG-ADL score with your doctor to keep them up to date.

Learn more about the importance of symptom tracking at VYVGARTSymptomTracking.com.

SELECT IMPORTANT SAFETY INFORMATION

Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you: take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines; have received or are scheduled to receive a vaccine (immunization); or have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

Please see Important Safety Information throughout. Please see the full Prescribing Information for <u>VYVGART for IV infusion</u> and <u>VYVGART HYTRULO</u> <u>for subcutaneous injection</u>.

THE MG-ADL SCALE

The **Myasthenia Gravis Activities of Daily Living (MG-ADL)** scale assesses the impact of generalized myasthenia gravis (gMG) on daily functions by measuring 8 signs or symptoms that are commonly affected in gMG. Each item is measured on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents the loss of ability to perform that function. Total scores range from 0 to 24 points, with a higher score showing more severe gMG.

Grade	o	1	2	3	Score (0, 1, 2, or 3)
1. Talking	Normal	Intermittent slurring or nasal speech	Constant slurring or nasal, but can be understood	Difficult to understand speech	
2. Chewing	Normal	Fatigue with solid food	Fatigue with soft food	Gastric tube	_ <u>_</u>
3. Swallowing	Normal	Rare episode of choking	Frequent choking necessitating changes in diet	Gastric tube	
4. Breathing	Normal	Shortness of breath with exertion	Shortness of breath at rest	Ventilator dependence	T
5. Impairment of ability to brush teeth or comb hair	None	Extra effort, but no rest periods needed	Rest periods needed	Cannot do one of these functions	
6. Impairment of ability to arise from a chair	None	Mild, sometimes uses arms	Moderate, always uses arms	Severe, requires assistance	
7. Double vision	None	Occurs, but not daily	Daily, but not constant	Constant	T
8. Eyelid droop	None	Occurs, but not daily	Daily, but not constant	Constant	T
MG-ADL score total = Add lines 1-8					

This information has been provided for educational purposes only and is not meant to be a substitute for professional medical advice. Patients should not use this information for diagnosing a health condition. Patients should always consult a healthcare professional for medical advice or information about diagnosis and treatment.

Source: Wolfe GI, et al. Neurology. 1999;52(7):1487-1489.

IMPORTANT SAFETY INFORMATION

Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART. Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART and VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

VYVGART and VYVGART HYTRULO may cause serious side effects, including:

- Infection. VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain.
- Allergic Reactions (hypersensitivity reactions). VYVGART and VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab.
- Infusion-Related Reactions. VYVGART and VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain.

Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART or VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction.

Before taking VYVGART or VYVGART HYTRULO, tell your doctor if you:

- take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines,
- have received or are scheduled to receive a vaccine (immunization), or
- have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding.

What are the common side effects of VYVGART and VYVGART HYTRULO?

The most common side effects in efgartigimodalfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives.

These are not all the possible side effects of VYVGART and VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfafcab) for intravenous (IV) infusion and what is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines, each used to treat a condition called generalized myasthenia gravis, which causes muscles to tire and weaken easily throughout the body, in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive).

Please see the full Prescribing Information for <u>VYVGART</u> and the full Prescribing Information for <u>VYVGART</u> <u>HYTRULO</u>, and talk to your doctor.

VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx. For U.S. audiences only. ©2024 argenx US-VYV-24-00027 VI 06/2024

